Consistent with previous studies, we found decreased response to IL-2 in the CD25lo population of T1D subjects ([11] and Figure 1B), although we did not find this same decrease in the CD25lo cells of MS or SLE patients. Here, IL2 is linked to myeloid sarcoma.